|Day Low/High||21.29 / 22.14|
|52 Wk Low/High||28.82 / 46.24|
The most recent short interest data was recently released for the 07/29/2016 settlement date, and Myriad Genetics, Inc. is one of the most shorted stocks of the Russell 3000, based on 21.79 "days to cover" versus the median component at 6.42.
AIR, DO, MLNX, HALL and MYGN were all recently downgraded by TheStreet's Quant Ratings.
Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, ARES, BREW, CHTR, FSIC, GBDC, IPAR, LUK, LUNA, NRCIA, ODP, OLED, PIP, STRL, VIPS Downgrades: BCRH, CBNK, DF, HALL, MDVN, MYGN, NMR, NYRT, SGU, TCRD, TEO Initiations: APPF, GLPI, SPNE, TDOC Read on to get TheStreet Quant Ratings' detailed report:
Here's a technical look at how to trade some of the most active stocks on the market right now.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
Following Tuesday's market close, Myriad Genetics (MYGN) reported lower-than-expected earnings for the 2016 fourth quarter and lowered guidance for the year.
Here are Wednesday's top research calls, including upgrades for Coach and Yelp, and downgrades for SunPower and Wayfair.
Allows Entry Into Attractive High-Growth Neuroscience Market
Here are Friday's top research calls, including downgrades for Harley-Davidson and Ford, an upgrade for Dow Chemical and new coverage on Target.
myChoice HRD Increases Eligible Patients by Approximately Twofold
Three Studies Demonstrate the Utility of Vectra DA to Help Predict Treatment Response and Remission in Patients with RA
New Studies at the 2016 ASCO Annual Meeting Demonstrate a 2- to 40-Fold Increased Risk
New Data Highlight the Power of the Myriad myRisk® Hereditary Cancer Test To Identify More Mutation Carriers Without Increased Risk of Distress
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®
Data Demonstrate Expanded Utility of the Myriad myRisk® Hereditary Cancer Test
New Data Highlight the Power of the Prolaris® Test to Predict 10-Year Oncologic Outcomes in Patients with Low-Risk Localized Prostate Cancer